title: Fingolimod (Gilenya) and melanoma.
abstract: The Food and Drug Administration (FDA) had approved fingolimod usage for multiple sclerosis in 2010. Melanoma after the usage of fingolimod immunomodulation was reported rarely in clinical trials, and only two case reports exist in the published literature, both occurring in Europe. Most of the incidences reported in clinical trials were in-situ, whereas both case reports were of malignant melanoma. Fingolimod has been found to inhibit metastatic melanoma growth in a mouse model that depends on vascular endothelial growth factor (VEGF)-induced angiogenesis for metastasis. However, there are numerous pathways of angiogenesis and tumour growth found in vivo by which melanoma can expand that do not mandate VEGF. We report a case of superficial spreading malignant melanoma occurring after fingolimod therapy in the USA.
authors.affiliation: Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
authors.forename: Christopher Lee
authors.initials: CL
authors.lastname: Robinson
authors.affiliation: Department of Dermatology, St. Louis University, St. Louis, Missouri, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Guo
mesh_terms: D005260:Female; D000068876:Fingolimod Hydrochloride / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008545:Melanoma / Q000139:chemically induced* / Q000601:surgery; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000601:surgery; D000096142:Cutaneous Malignant Melanoma
chemical_list: D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride